• Kryptowährungen
  • Prognosemärkte
  • Nachrichten
  • Agentic Trading
  • Artikel
  • Ligen

Suche Kryptowährungen

Trendende Kryptowährungen

CoinRithm

Firma

Rechtsträger
Bees-x Limited
Unternehmensnummer
13308136
Eingetragen in
England and Wales
Eingetragener Sitz
Monmouth House, High Street, Watford, England, WD17 1LN

CoinRithm ist ein Informations- und Recherchedienst der Bees-x Limited. Das Unternehmen ist von der Financial Conduct Authority (FCA) nicht zur Ausübung regulierter Tätigkeiten zugelassen, und nichts auf dieser Website stellt Finanzberatung dar.

Entdecken

KryptowährungenPrognosemärkteNachrichtenArtikelAgent ArenaLigen

Funktionen

DashboardProbespielAgentic TradingPortfolioBeobachtungslisteEinstellungen

Firma

Über UnsMethodikNutzungsbedingungenDatenschutzrichtlinieCookie-RichtlinieHaftungsausschluss

Support

KundendienstFAQEntwickler-KitMCP-Dokumentation

Soziale Medien

X (Twitter)FacebookLinkedInTelegramInstagramTikTokYouTube
© 2026 CoinRithm. Alle Rechte vorbehalten.
Jetzt bei Google PlayLaden im App Store
  • Start
  • MärktePrognosemärkte
  • Nachrichten
  • Dashboard
  1. Prognosemärkte
  2. Health & Medicine
  3. What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?
Manifold Markets

What will the phase 3 clinical trial results report for vaccine efficacy (%) of the R21 malaria vaccine at 48 months?

Health & MedicineOne-Off2Mon
Manifold MarketsManifold MarketsKein KYC
Aktuelle Community-Prognose
Manifold Markets
20-29% 9.4%
Führend unter 7 Optionen
Prognostiker

11

Fragetyp

multiple choice

Methodik

Play-money forecasting platform

Quellentyp

Prognose

Marktdaten

Aktualisiert vorgestern

Veraltet
15. März 24, 21:292. Sept. 26, 6:59

Trends

Ergebnis24hWahrscheinlichkeit

Gewähltes Ergebnis

20-29%9%

Regeln

The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.

Manifold Markets
  • Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
  • Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2026).
  • Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
  • 1Day Sooner has an R21 Status Report available here that may be useful.
  • More malaria-related questions can be found on our Manifold account here.

Verwandte Märkte

Hantavirus pandemic in 2026?

Hantavirus pandemic in 2026?

145.259,6 €
Ja: 5%PolymarketPOLYMARKET
New pandemic in 2026?

New pandemic in 2026?

16.626,4 €
Ja: 10%PolymarketPOLYMARKET
Ebola pandemic in 2026?

Ebola pandemic in 2026?

8708 €
Ja: 8%PolymarketPOLYMARKET
Manifold Markets

How many movies will gross >$1 billion in 2026?

1257,8 €
0-3: 5.7%Manifold MarketsMANIFOLD MARKETS
Manifold Markets

Which disease will be eradicated next in humans?

462,5 €
Polio: 26.7%Manifold MarketsMANIFOLD MARKETS
When, where or how will Trump die?

When, where or how will Trump die?

137,8 €
2025: 0%Manifold MarketsMANIFOLD MARKETS

In diesen Themen aktiv

BitcoinBTC$62,928.32+2.44%EthereumETH$1,659.49+1.68%SolanaSOL$65.34+1.62%DogecoinDOGE$0.085+1.53%XRPXRP$1.12+0.39%BNBBNB$596.89+1.78%

Verwandte Nachrichten

Chainalysis reveals $100 million peptide market built on cryptoCrypto NewsGray peptide vendors embrace stablecoins as safety fears deepenCrypto NewsOpenAI Expands GPT-Rosalind Access with Rosalind BiodefenseBlockchain.NewsOpenAI Expands GPT-Rosalind Capabilities for Life SciencesBlockchain.NewsBrian Armstrong’s NewLimit Raises $435M for Human TrialsCrypto News

Regeln

The 12 month phase 3 data indicates 75% vaccine efficacy of R21 in annual malaria sites in children at 12 months after the first dose was delivered.

Manifold Markets
  • Phase 2b data at a 42 month timepoint showed 71% efficacy after four total doses (Abstract here, #6949).
  • Resolves upon publication of peer-reviewed data from the R21 team at Oxford (expected to be before September 1st, 2026).
  • Vaccine efficacy is defined as the primary endpoint for time to clinical malaria in seasonal sites, as defined in the paper linked above.
  • 1Day Sooner has an R21 Status Report available here that may be useful.
  • More malaria-related questions can be found on our Manifold account here.